Bayer buys Algeta

Share this article:

Bayer is ponying up $2.9 billion to buy now-former oncology partner Algeta, reports PMLive. The deal means Bayer will own the prostate cancer therapy Xofigo outright.

The company previously estimated the alpha-particle-emitting therapeutic agent would hit $1.3 billion in annual sales.

The FDA approved the treatment in May.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.